Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Misty Shields

Thoracic Oncology · IUSM

View

Dr. Gilberto Lopes

Thoracic Oncology · University of Miami

View

Dr. Jacob Sands

Thoracic Oncology · Dana-Farber Cancer Institute

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    DCDr. David Camidge

    Dr. David Camidge

    Medical Oncology · Thoracic Oncology
    University of Colorado Anschutz
    davidcamidge

    Research

    Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).

    2026

    Via ESMO Open

    Research

    Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.

    2025

    Via Clinical Cancer Research

    Research

    Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group.

    2025

    Via Lung Cancer

    Research

    Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.

    2025

    Via Lung Cancer

    Research

    A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.

    2025

    Via Lung Cancer

    Research

    Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.

    2025

    Via Cell Reports Medicine

    Research

    Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.

    2025

    Via Clinical Lung Cancer

    Research

    Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

    2025

    Via Nature Communications

    Research

    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

    2024

    Via Journal of Clinical Oncology

    Research

    A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.

    2024

    Via Clinical Lung Cancer

    Research

    CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

    2024

    Via Nature

    Research

    Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.

    2024

    Via Journal of Thoracic Oncology

    Research

    Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.

    2024

    Via Pharmacoepidemiology and Drug Safety

    Research

    Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.

    2024

    Via JTO Clinical and Research Reports

    Research

    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.

    2023

    Via Journal of Thoracic Oncology